BioCentury | Jan 13, 2021
Deals

Boehringer accesses untouched cancer targets through Enara deal

...control. Enara, which debuted in late 2019 as Ervaxx Ltd....
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

...bone and ovarian cancer cells, while remaining inert to non-cancerous cells. Enara Bio Ltd., formerly Ervaxx Ltd....
...HLALS) - Major histocompatibility complex, class I-related TCR - T cell receptor Danielle Golovin, Staff Writer Versant Ventures Ervaxx Ltd. Cardiff...
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...and Kira Nelson as VP, finance. At least two other companies, GeNeuro S.A. (Euronext:GNRO) and Ervaxx Ltd....
BioCentury | Jan 25, 2020
Preclinical News

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

...go beyond targeting neoantigens derived from typically unexpressed DNA, to tumor antigens that aren’t peptides. Ervaxx Ltd....
...HLALS) - Major histocompatibility complex, class I-related; TCR - T cell receptor Sandi Wong, Assistant Editor Cardiff University Ervaxx Ltd. neoantigen Major...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

...He said Ervaxx is undecided as to whether it would partner these therapies. COMPANY PROFILE Ervaxx Ltd....
...$16.8 million) Investors: SV Health Investors CEO: Kevin Pojasek Patents: No issued patents Stephen Hansen, Associate Editor Ervaxx Ltd. neoantigen...
BioCentury | Aug 30, 2018
Targets & Mechanisms

Alt-neoantigens

...practice. Houman Ashrafian, a partner at SV Health Investors and investor in cancer vaccine company Ervaxx Ltd....
Items per page:
1 - 6 of 6
BioCentury | Jan 13, 2021
Deals

Boehringer accesses untouched cancer targets through Enara deal

...control. Enara, which debuted in late 2019 as Ervaxx Ltd....
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

...bone and ovarian cancer cells, while remaining inert to non-cancerous cells. Enara Bio Ltd., formerly Ervaxx Ltd....
...HLALS) - Major histocompatibility complex, class I-related TCR - T cell receptor Danielle Golovin, Staff Writer Versant Ventures Ervaxx Ltd. Cardiff...
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...and Kira Nelson as VP, finance. At least two other companies, GeNeuro S.A. (Euronext:GNRO) and Ervaxx Ltd....
BioCentury | Jan 25, 2020
Preclinical News

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

...go beyond targeting neoantigens derived from typically unexpressed DNA, to tumor antigens that aren’t peptides. Ervaxx Ltd....
...HLALS) - Major histocompatibility complex, class I-related; TCR - T cell receptor Sandi Wong, Assistant Editor Cardiff University Ervaxx Ltd. neoantigen Major...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

...He said Ervaxx is undecided as to whether it would partner these therapies. COMPANY PROFILE Ervaxx Ltd....
...$16.8 million) Investors: SV Health Investors CEO: Kevin Pojasek Patents: No issued patents Stephen Hansen, Associate Editor Ervaxx Ltd. neoantigen...
BioCentury | Aug 30, 2018
Targets & Mechanisms

Alt-neoantigens

...practice. Houman Ashrafian, a partner at SV Health Investors and investor in cancer vaccine company Ervaxx Ltd....
Items per page:
1 - 6 of 6